DAVIDSON EWUZIE: Open Payments
NPI 1508406018 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$752 in 37 payments from 13 companies in 2025. Trend: 2023 $860 · 2024 $571 · 2025 $752
Food & beverage: $752
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $141 |
| Lundbeck LLC | 4 | $82 |
| Axsome Therapeutics, Inc. | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Alkermes, Inc. | 2 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $46 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| ABBVIE INC. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
Products named: REXULTI, CAPLYTA, Auvelity, FANAPT, ARISTADA, Qelbree, INGREZZA, VRAYLAR.
Industry payments across TX — which companies pay providers there.
